German Cancer Consortium (DKTK)

The German Cancer Consortium (“Deutsches Konsortium für Translationale Krebsforschung”, DKTK) is a joint, long-term initiative of the Federal Ministry of Research, Technology and Space (BMFTR), the participating federal states and the German Cancer Research Center (DKFZ) as the core center.

Logo of the DKTK (German Consortium for Translational Cancer Research), featuring the acronym “DKTK” in bold, accompanied by the full name in German. The design includes a grid pattern of colored squares to the left of the text.

Who we are

A map of Germany highlighting key cities involved in a translational research network. Marked locations include Berlin, Essen/Düsseldorf, Dresden, Frankfurt/Mainz, Heidelberg, Tübingen, Freiburg, and München, illustrating regional collaboration in cancer research.

In 2012, the German Cancer Consortium (“Deutsches Konsortium für Translationale Krebsforschung”, DKTK), was founded as one of the German Centers for Health Research (“Deutsche Zentren der Gesundheitsforschung”, DZG). The mission of DKTK is to make advances in prevention, diagnostics, early detection and therapy of cancer usable for patients more quickly through translational research. Scientists in the DKTK primarily work on preclinical translational research topics – meaning at the interface between basic and clinical research. It also supports reverse translation in order to follow-up on study results that require further scientific elucidation.

DKTK is a joint long-term initiative of the Federal Ministry of Research, Technology and Space (BMFTR), the participating federal states and the German Cancer Research Center (DKFZ). In its role as DKTK’s core center, the DKFZ joins forces with more than 20 research institutions and university clinics with particular oncological expertise in translation centers at eight partner sites in Germany: Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich and Tübingen.

 

 

More than 1,000 researchers from both the natural sciences and medicine are currently engaged within the DKTK. A key objective of the Consortium is to establish long-term research infrastructures at the DKTK sites that are jointly used. By leading an independent DKTK Junior Research Group or being appointed to W2/3 professorships, talented scientists can take their next career step and make valuable contributions to translational oncology. Below is a list of the current department and group heads: 

Joint Funding Program

Form

Form data is loaded ...